Polymorphisms in LPL CETP and HL protect HIV-infected patients from atherogenic dyslipidemia in an allele-dose-dependent manner

摘要

IntroductionHIV-infected patients treated with Highly Active Antiretroviral Therapy (HAART) may be predisposed to hypertriglyceridemia, which gives rise to a highly atherogenic lipid profile known as atherogenic dyslipidemia (AD). We propose that genetic variability leaves some HIV-infected patients more predisposed to AD than others [, ].